Trends in the use and abuse of branded and generic extended release oxycodone and fentanyl products in the United States

Drug and Alcohol Dependence

Volumn 91, Issue 2-3, 2007, Pages 115-120

  Cicero, Theodore J ^a   Inciardi, James A ^b   Surratt, Hilary ^b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF DELAWARE   (United States)

Author keywords

Fentanyl; Generics; Opioids; Oxycodone; Pharmacoeconomics; Prescription drug abuse

Indexed keywords

FENTANYL; OXYCODONE;

ARTICLE; DRUG ABUSE; DRUG COST; DRUG MARKETING; DRUG USE; HUMAN; PRESCRIPTION; PRIORITY JOURNAL; UNITED STATES;

DELAYED-ACTION PREPARATIONS; DRUGS, GENERIC; FENTANYL; HUMANS; OXYCODONE; PRESCRIPTIONS, DRUG; QUESTIONNAIRES; SUBSTANCE-RELATED DISORDERS; UNITED STATES;

NICOTIANA TABACUM;

EID: 35148887704     PISSN: 03768716     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2007.05.008     Document Type: Article

References (27)

1. Adams E.H., Breiner S., Cicero T.J., Geller A., Inciardi J.A., Schnoll S.H., Senay E.C., and Woody G.E. A comparison of the abuse liability of tramadol, NSAIDs and hydrocodone in patients with chronic pain. J. Pain Symptom Manage. 31 5 (2006) 465-476
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. fourth ed. (1994), American Psychiatric Association, Washington, DC
3. ® (oxycodone HCl controlled-release) tablets on the abuse of oxycodone. Drug Alcohol Depend. 84 2 (2006) 182-187
4. Campo K., De Satebel O., Gijsbrechts E., and Van Waterschoot W. Physicians' decision process for drug prescription and the impact of pharmaceutical marketing mix instruments. Health Mark Q 22 4 (2005) 73-107
5. Caulkins J.P. Drug prices and emergency department mentions for cocaine and heroin. Am. J. Public Health 91 9 (2001) 1446-1448
6. Cicero T.J., Adams E.H., Geller A., Inciardi J.A., Muñoz A., Schnoll S.H., Senay E.C., and Woody G.E. A post-marketing surveillance program to monitor Ultram (tramadol hydrochloride) abuse in the United States. Drug Alcohol Depend. 57 1 (1999) 7-22
7. Cicero T.J., Inciardi J.A., Adams E.H., Geller A., Senay E.C., Woody G.E., and Munoz A. Rates of abuse of tramadol remain unchanged with the introduction of new branded and generic products: results of an abuse monitoring system: 1994-2004. Pharmacoepidemiol. Drug Saf. 14 12 (2005) 851-859
8. Cicero T.J., and Inciardi J.A. Diversion and abuse of methadone prescribed for pain management. JAMA 293 3 (2005) 297-298
9. Cicero T.J., Inciardi J.A., and Munoz A. Trends in abuse of OxyContin and other opioid analgesics in the United States: 2002-2004. J. Pain 6 10 (2005) 662-672
10. Cicero, T.J., Surratt, H., Inciardi, J.A., 2007. Relationship between therapeutic use and abuse of opioid analgesic in rural, suburban and urban locations in the United States. Pharmacoepidemiol. Drug Saf., in press.
11. DeWitt E.M., Glick H.A., Albert D.A., Marshall J.M., and Wolf F. Medicare coverage of tumor necrosis factor α inhibitors as an influence on physicians' prescribing behavior. Arch. Intern. Med. 166 1 (2006) 57-63
12. Federman A.D., Adams A.S., Ross-Degnan D., Soumerai S.B., and Ayanian J.Z. Supplemental insurance and use of effective cardiovascular drugs among elderly medicare beneficiaries with coronary heart disease. JAMA 286 14 (2001) 1732-1739
13. Goldman D.P., Joyce G.F., Escarce J.J., Pace J.E., Solomon M.D., Laouri M., Landsman P.B., and Teutsch S.M. Pharmacy benefits and the use of drugs by the chronically ill. JAMA 291 19 (2004) 2344-2350
14. Huskamp H.A., Deverka P.A., Epstein A.M., Epstein R.S., McGuigan K.A., Muriel A.C., and Frank R.G. Impact of 3-tier formularies on drug treatment of attention-deficit/hyperactivity disorder in children. Arch. Gen. Psychiatry 62 4 (2005) 435-441
15. Hyatt Jr. R.R., and Rhodes W. The price and purity of cocaine: the relationship to emergency room visits and death and to drug use among arrestees. Stat. Med. 14 5-7 (1995) 655-668
16. Hyland A., Bauer J.E., Li Q., Abrams S.M., Higbee C., Peppone L., and Cummings K.M. Higher cigarette prices influence cigarette purchase patterns. Tob. Control 14 2 (2005) 86-92
17. ® and Generic Tramadol HCL. J. Addict. Dis. 25 2 (2006) 53-58
18. Monnet D.L., Ferech M., Frimodt-Moller N., and Goossens H. The more antibacterial trade names, the more consumption of antibacterials: a European study. Clin. Infect. Dis. 41 1 (2005) 114-117
19. Paterson J.M., Mamdani M., Juurlink D.N., Naglie G., Laupacis A., and Stukel T.A. Clinical consequences of generic Warfarin substitution: an ecological study. Res. Lett. JAMA 296 16 (2006) 1969-1972
20. Petry N.M. A behavioral economic analysis of poly-drug abuse in alcoholics: asymmetrical substitution of alcohol and cocaine. Drug Alcohol Depend. 62 1 (2001) 31-39
21. Plamper E., Klever Deichert G., and Lauterbach K.W. Effects of tobacco tax increase on cigarette consumption and the impact on health policy. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 49 7 (2006) 660-664
22. Sloan F.A., Reilly B.A., and Schenzler C. Effects of prices, civil and criminal sanctions, and law enforcement on alcohol-related mortality. J. Stud. Alcohol 55 4 (1994) 454-465
23. Smith D.G. The effects of copayments and generic substitution on the use and costs of prescription drugs. Inquiry 30 2 (1993) 189-198
24. Taira D.A., Iwane K.A., and Chung R.S. Prescription drugs: elderly enrollee reports of financial access, receipt of free samples and discussion of generic equivalents related to type of coverage. Am. J. Manag. Care 9 4 (2003) 305-312
25. Wadland W.C., Farquhar L., Priester F., Oberst K., and Weismantel D.P. Increasing generic prescribing: a resident educational intervention. Farm Med. 37 4 (2005) 259-264
26. Walker S., and Willey C.W. Impact on drug costs and utilization of a clinical pharmacist in a multisite primary care medical group. J. Manag. Care Pharm. 10 4 (2004) 345-354
27. Zhang B., Cohen J., Ferrence R., and Rehm J. The impact of tobacco tax cuts on smoking initiation among Canadian young adults. Am. J. Prev. Med. 30 6 (2006) 474-479